Filter

Refine by collections

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 11 items for :

  • "spartalizumab" x
  • Refine by access: All content x
Clear All
James C Yao University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Search for other papers by James C Yao in
Google Scholar
PubMed Close
,
Jonathan Strosberg Department of GI Oncology, Moffitt Cancer Center, Tampa, Florida, USA

Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed Close
,
Nicola Fazio European Institute of Oncology, IEO, IRCCS, Milan, Italy

Search for other papers by Nicola Fazio in
Google Scholar
PubMed Close
,
Marianne E Pavel Department of Medicine 1, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany

Search for other papers by Marianne E Pavel in
Google Scholar
PubMed Close
,
Emily Bergsland UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA

Search for other papers by Emily Bergsland in
Google Scholar
PubMed Close
,
Philippe Ruszniewski Hôpital Beaujon, University of Paris, Paris, France

Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed Close
,
Daniel M Halperin University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Search for other papers by Daniel M Halperin in
Google Scholar
PubMed Close
,
Daneng Li City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, California, USA

Search for other papers by Daneng Li in
Google Scholar
PubMed Close
,
Salvatore Tafuto Sarcomas and Rare Tumours Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy

Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed Close
,
Nitya Raj Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for other papers by Nitya Raj in
Google Scholar
PubMed Close
,
Davide Campana Department of Clinical Medicine, Sant’Orsola-Malpighi Hospital, University of Bologna, ENETS Center of Excellence, Bologna, Italy

Search for other papers by Davide Campana in
Google Scholar
PubMed Close
,
Susumu Hijioka National Cancer Center Japan Tsukiji Campus, Department of Hepatobiliary and Pancreatic Oncology, Tokyo, Japan

Search for other papers by Susumu Hijioka in
Google Scholar
PubMed Close
,
Markus Raderer Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria

Search for other papers by Markus Raderer in
Google Scholar
PubMed Close
,
Rosine Guimbaud CHU de Toulouse, Toulouse, France

Search for other papers by Rosine Guimbaud in
Google Scholar
PubMed Close
,
Pablo Gajate Hospital Universitário Ramón y Cajal, Clinical Oncology Department, Madrid, Spain

Search for other papers by Pablo Gajate in
Google Scholar
PubMed Close
,
Sara Pusceddu Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Search for other papers by Sara Pusceddu in
Google Scholar
PubMed Close
,
Albert Reising Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Search for other papers by Albert Reising in
Google Scholar
PubMed Close
,
Evgeny Degtyarev Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Search for other papers by Evgeny Degtyarev in
Google Scholar
PubMed Close
,
Mark Shilkrut Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Search for other papers by Mark Shilkrut in
Google Scholar
PubMed Close
,
Simantini Eddy Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Search for other papers by Simantini Eddy in
Google Scholar
PubMed Close
, and
Simron Singh Sunnybrook Health Sciences Centre, Toronto, Canada

Search for other papers by Simron Singh in
Google Scholar
PubMed Close

. Immunotherapy has been studied to a limited extend in NENs, demonstrating low objective response rates ( Mehnert et al. 2020 ). Spartalizumab (PDR001) is a high-affinity, ligand-blocking, humanized IgG4 antibody directed against PD-1 receptor, that blocks

Article Type:
Research Article
Collections:
Top-cited articles of 2023
DOI:
https://doi.org/10.1530/ERC-20-0382
Volume/Issue:
Volume 28: Issue 3
Restricted access
Anna Angelousi 1st Department of Internal Medicine, Unit of Endocrinology, Laikon Hospital, Athens, Greece

Search for other papers by Anna Angelousi in
Google Scholar
PubMed Close
,
Ploutarchos Tzoulis Department of Metabolism & Experimental Therapeutics, Division of Medicine, University College London, London, UK

Search for other papers by Ploutarchos Tzoulis in
Google Scholar
PubMed Close
,
Marina Tsoli 1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Marina Tsoli in
Google Scholar
PubMed Close
,
Eleftherios Chatzellis 251 HAF and VA Hospital, Athens, Greece

Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed Close
,
Anna Koumarianou Fourth Department of Internal Medicine, Hematology Oncology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Greece

Search for other papers by Anna Koumarianou in
Google Scholar
PubMed Close
, and
Gregory Kaltsas 1st Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed Close

alone in ATC ( Capdevila et al. 2020 , De Leo et al. 2020 , Boudin et al. 2022 , Hatashima et al. 2022 ). The first, a phase II study evaluating spartalizumab, a monoclonal antibody against PD-1 receptor, in patients with locally advanced

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-23-0296
Volume/Issue:
Volume 31: Issue 4
Restricted access
A Mohamed Division of Hematology and Medical Oncology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by A Mohamed in
Google Scholar
PubMed Close
,
M Trybula Division of Hematology and Medical Oncology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by M Trybula in
Google Scholar
PubMed Close
,
S L Asa Department of Medicine, UH Seidman Cancer Center Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by S L Asa in
Google Scholar
PubMed Close
,
T R Halfdanarson Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA

Search for other papers by T R Halfdanarson in
Google Scholar
PubMed Close
, and
M B Sonbol Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, USA

Search for other papers by M B Sonbol in
Google Scholar
PubMed Close

-institution experiences ( Table 3 ). A phase II multicenter trial for spartalizumab in patients with both GEP and thoracic NENs showed a low ORR (7.4% in well-differentiated G3 GEP NETs and 4.8% in GEP NECs) ( Yao et al. 2021 ). Although Ki-67 was > 20% in some of the

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-24-0025
Volume/Issue:
Volume 31: Issue 10
Restricted access
Clotilde Sparano Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France
Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences ‘Mario Serio’, University of Florence, Florence, Italy

Search for other papers by Clotilde Sparano in
Google Scholar
PubMed Close
,
Yann Godbert Nuclear Medicine, and Thyroid Oncology Department, Institut Bergonié, Bordeaux, France

Search for other papers by Yann Godbert in
Google Scholar
PubMed Close
,
Marie Attard Radiology, Gustave Roussy and Université Paris Saclay, Villejuif, France

Search for other papers by Marie Attard in
Google Scholar
PubMed Close
,
Christine Do Cao Endocrinology, Diabetology and Metabolism, CHRU Lille, Lille, France

Search for other papers by Christine Do Cao in
Google Scholar
PubMed Close
,
Slimane Zerdoud Nuclear medicine, Claudius-Regaud Institute, Oncology University Institute-IUCT-Oncopole, Toulouse, France

Search for other papers by Slimane Zerdoud in
Google Scholar
PubMed Close
,
Nathalie Roudaut Department of Endocrinology, University Hospital of Brest, Brest, France

Search for other papers by Nathalie Roudaut in
Google Scholar
PubMed Close
,
Charlotte Joly Department of Oncology, Henri-Mondor Hospital, Créteil, France

Search for other papers by Charlotte Joly in
Google Scholar
PubMed Close
,
Amandine Berdelou Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France

Search for other papers by Amandine Berdelou in
Google Scholar
PubMed Close
,
Julien Hadoux Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France

Search for other papers by Julien Hadoux in
Google Scholar
PubMed Close
,
Livia Lamartina Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France

Search for other papers by Livia Lamartina in
Google Scholar
PubMed Close
,
Martin Schlumberger Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France

Search for other papers by Martin Schlumberger in
Google Scholar
PubMed Close
, and
Sophie Leboulleux Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close

II trial with spartalizumab showed promising and durable results in advanced ATC, with an overall response rate of 19% and also three cases of complete response, regardless of BRAF gene molecular status ( Capdevila et al. 2020 ). If early phase

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-20-0106
Volume/Issue:
Volume 28: Issue 1
Restricted access
Pedro Iglesias Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Majadahonda, Madrid, Spain

Search for other papers by Pedro Iglesias in
Google Scholar
PubMed Close
,
Inmaculada Peiró Clinical Nutrition Unit, Catalan Institute of Oncology, L’Hospitalet de Llobregat, Barcelona, Spain
Unit of Nutrition and Cancer-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

Search for other papers by Inmaculada Peiró in
Google Scholar
PubMed Close
,
Betina Biagetti Department of Endocrinology, Universitari Vall d’Hebron, Barcelona, Spain

Search for other papers by Betina Biagetti in
Google Scholar
PubMed Close
,
Miguel Paja-Fano Department of Endocrinology, Hospital Universitario de Basurto, Bilbao, Spain

Search for other papers by Miguel Paja-Fano in
Google Scholar
PubMed Close
,
Diana Ariadel Cobo Department of Endocrinology, Complejo Asistencial Universitario de León, León, Spain

Search for other papers by Diana Ariadel Cobo in
Google Scholar
PubMed Close
,
Carlos García Gómez Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain

Search for other papers by Carlos García Gómez in
Google Scholar
PubMed Close
,
Manuel Mateu-Salat Department of Endocrinology, Hospital Sant Pau, Hospital Sant Pau, Barcelona, Spain
Department of Medicine/Endocrinology, IIB-Sant Pau, Research Center for Pituitary Diseases, Barcelona, Spain

Search for other papers by Manuel Mateu-Salat in
Google Scholar
PubMed Close
,
Idoia Genua Department of Endocrinology, Hospital Sant Pau, Hospital Sant Pau, Barcelona, Spain
Department of Medicine/Endocrinology, IIB-Sant Pau, Research Center for Pituitary Diseases, Barcelona, Spain

Search for other papers by Idoia Genua in
Google Scholar
PubMed Close
,
Margarita Majem Department of Oncology, Hospital Sant Pau, Barcelona, Spain

Search for other papers by Margarita Majem in
Google Scholar
PubMed Close
,
Mariona Riudavets Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France

Search for other papers by Mariona Riudavets in
Google Scholar
PubMed Close
,
Javier Gavira Department of Oncology, Hospital Sant Pau, Barcelona, Spain

Search for other papers by Javier Gavira in
Google Scholar
PubMed Close
,
Cristina Lamas Department of Endocrinology, Hospital General Universitario de Albacete, Albacete, Spain

Search for other papers by Cristina Lamas in
Google Scholar
PubMed Close
,
Antía Fernández Pombo Department of Endocrinology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

Search for other papers by Antía Fernández Pombo in
Google Scholar
PubMed Close
,
Fernando Guerrero-Pérez Department of Endocrinology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

Search for other papers by Fernando Guerrero-Pérez in
Google Scholar
PubMed Close
,
Carles Villabona Department of Endocrinology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

Search for other papers by Carles Villabona in
Google Scholar
PubMed Close
,
José Manuel Cabezas Agrícola Department of Endocrinology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

Search for other papers by José Manuel Cabezas Agrícola in
Google Scholar
PubMed Close
,
Susan M Webb Department of Endocrinology, Hospital Sant Pau, Hospital Sant Pau, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Universitat Autònoma de Barcelona, Barcelona, Spain

Search for other papers by Susan M Webb in
Google Scholar
PubMed Close
, and
Juan J Díez Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana (IDIPHISA), Majadahonda, Madrid, Spain
Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

Search for other papers by Juan J Díez in
Google Scholar
PubMed Close

.7)  Atezolizumab 1 (2.7)  Tremelimumab 1 (2.7)  Spartalizumab 1 (2.7)  Others 3 (8.1) ICI regimen, n (%)  Monotherapy 27 (73.0)  Combined therapy 10 (27.0) Time to develop IAD after starting ICI (months

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-21-0228
Volume/Issue:
Volume 28: Issue 12
Restricted access
Philipp Melhorn Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

Search for other papers by Philipp Melhorn in
Google Scholar
PubMed Close
,
Peter Mazal Department of Pathology, Medical University of Vienna, Vienna, Austria

Search for other papers by Peter Mazal in
Google Scholar
PubMed Close
,
Ladislaia Wolff Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

Search for other papers by Ladislaia Wolff in
Google Scholar
PubMed Close
,
Petar Popov Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

Search for other papers by Petar Popov in
Google Scholar
PubMed Close
,
Elisabeth Kretschmer-Chott Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria

Search for other papers by Elisabeth Kretschmer-Chott in
Google Scholar
PubMed Close
,
Alexander Haug Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria

Search for other papers by Alexander Haug in
Google Scholar
PubMed Close
,
Marius E Mayerhoefer Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Weill Cornell Medical College, Cornell University, New York, New York, USA

Search for other papers by Marius E Mayerhoefer in
Google Scholar
PubMed Close
,
Markus Raderer Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

Search for other papers by Markus Raderer in
Google Scholar
PubMed Close
, and
Barbara Kiesewetter Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

Search for other papers by Barbara Kiesewetter in
Google Scholar
PubMed Close

, mediastinum, pleura, and psoas muscle; b Lanreotide/temozolomide, pembrolizumab, streptozotocin/doxorubicin, topotecan, ACO, EPICO, FOLFOX, spartalizumab, and investigational medicinal product. Treatment specifics The median number of TEMCAP

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-23-0151
Volume/Issue:
Volume 31: Issue 3
Restricted access
Andrew McDonald Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Andrew McDonald in
Google Scholar
PubMed Close
,
Vaidehi Avadhani Grady Memorial Hospital, Atlanta, Georgia, USA

Search for other papers by Vaidehi Avadhani in
Google Scholar
PubMed Close
,
Gabriela Oprea-Ilies Grady Memorial Hospital, Atlanta, Georgia, USA

Search for other papers by Gabriela Oprea-Ilies in
Google Scholar
PubMed Close
,
Katerina Zakka Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Katerina Zakka in
Google Scholar
PubMed Close
,
Gregory B Lesinski Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Gregory B Lesinski in
Google Scholar
PubMed Close
,
Olumide B Gbolahan Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Olumide B Gbolahan in
Google Scholar
PubMed Close
, and
Olatunji Alese Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Olatunji Alese in
Google Scholar
PubMed Close

DM Li D Tafuto S Raj N , et al. 2021 Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms . Endocrine-Related Cancer 28 161 – 172 . ( https://doi.org/10.1530/ERC-20-0382 ) Ye L Ye H Zhou Q Li Z Lin Q Tan

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-24-0046
Volume/Issue:
Volume 31: Issue 10
Restricted access
Tim J Takkenkamp Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Tim J Takkenkamp in
Google Scholar
PubMed Close
,
Mathilde Jalving Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Mathilde Jalving in
Google Scholar
PubMed Close
,
Frederik J H Hoogwater Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Frederik J H Hoogwater in
Google Scholar
PubMed Close
, and
Annemiek M E Walenkamp Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Annemiek M E Walenkamp in
Google Scholar
PubMed Close

NECs (GEP-NECs) ( n  = 21). The study analysed spartalizumab, a PD-1 inhibitor, and found that in the well-differentiated cohort, there were seven partial responses (7%) and 55% had stable disease, while 31% had progressive disease. The confirmed

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-20-0113
Volume/Issue:
Volume 27: Issue 9
Free access
Mairéad G McNamara Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
Division of Cancer Sciences, University of Manchester, Manchester, UK

Search for other papers by Mairéad G McNamara in
Google Scholar
PubMed Close
,
Jean-Yves Scoazec Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France
Université Paris Sud, Faculté de Médecine de Bicêtre, Le Kremlin-Bicêtre, France

Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed Close
, and
Thomas Walter Department of Gastroenterology and Medical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France

Search for other papers by Thomas Walter in
Google Scholar
PubMed Close

studies, thus far, have been conflicting. In preliminary analysis of a phase II study (NCT 02955069), the activity and safety of spartalizumab (PDR001), a high-affinity, humanised, anti-PD-1 IgG4 antibody that blocks PD-L1 and PD-L2 binding to PD-1, was

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-19-0483
Volume/Issue:
Volume 27: Issue 7
Free access
Halfdan Sorbye Department of Oncology, Haukeland University Hospital, Bergen, Norway
Department of Clinical Sciences, University of Bergen, Bergen, Norway

Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed Close
,
Grace Kong Department of Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

Search for other papers by Grace Kong in
Google Scholar
PubMed Close
, and
Simona Grozinsky-Glasberg Neuroendocrine Tumor Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed Close

Bergsland E , et al . 2018 Activity and safety of spartalizumab (PDR001) in patients with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, and gastroenteropancreatic neuroendocrine carcinoma (GEP

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-19-0400
Volume/Issue:
Volume 27: Issue 3
Free access